| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T725 |
0-181 |
Sentence |
denotes |
Together, these studies demonstrated that acute enteral or parenteral administration of n-3 PUFAs in the setting of severe illness could significantly improve the clinical outcomes. |
| T726 |
182-514 |
Sentence |
denotes |
Notably, it has been shown that fish oil emulsions containing substantial amounts of EPA and DHA have an excellent safety record in both critically ill adults and children (Calder, 2009, Calder, 2019; Nandivada, Fell, Gura, & Puder, 2016) making them a suitable candidate for use in severe stress conditions as in COVID-19 patients. |
| T727 |
515-729 |
Sentence |
denotes |
However, with the research that has been completed to date, it is not possible to definitively determine the dose, route of administration and the best timing to intervene with n-3 PUFAs in the setting of COVID-19. |
| T728 |
730-1036 |
Sentence |
denotes |
More research is undoubtedly needed before definitive recommendations about the routine use of n-3 PUFAs in the context of COVID-19 can be made particularly that dosing data and pharmacokinetics studies of both enteral and parenteral n-3 PUFAs in critically ill patients are highly variable and incomplete. |
